Aiming For Better, Cheaper ERT Drugs, Oxyrane Raises $26.5 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K biotech Oxyrane raises $26.5 million D round to advance enzyme replacement therapies and validate a technology platform that may lead to cheaper-to-produce and more effective ERTs